JP2021522228A5 - - Google Patents
Info
- Publication number
- JP2021522228A5 JP2021522228A5 JP2020558887A JP2020558887A JP2021522228A5 JP 2021522228 A5 JP2021522228 A5 JP 2021522228A5 JP 2020558887 A JP2020558887 A JP 2020558887A JP 2020558887 A JP2020558887 A JP 2020558887A JP 2021522228 A5 JP2021522228 A5 JP 2021522228A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- formula
- composition according
- carbon atoms
- rna
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18169325 | 2018-04-25 | ||
| EP18169325.0 | 2018-04-25 | ||
| EP18189010 | 2018-08-14 | ||
| EP18189010.4 | 2018-08-14 | ||
| PCT/EP2019/060644 WO2019207060A1 (en) | 2018-04-25 | 2019-04-25 | Lipid-based formulations for the delivery of rna |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522228A JP2021522228A (ja) | 2021-08-30 |
| JP2021522228A5 true JP2021522228A5 (https=) | 2022-05-02 |
| JPWO2019207060A5 JPWO2019207060A5 (https=) | 2022-05-02 |
Family
ID=66240151
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559465A Active JP7256824B2 (ja) | 2018-04-25 | 2019-04-25 | 粒子状製剤用の凍結保護剤 |
| JP2020558887A Pending JP2021522228A (ja) | 2018-04-25 | 2019-04-25 | Ｒｎａの送達用の脂質に基づく製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559465A Active JP7256824B2 (ja) | 2018-04-25 | 2019-04-25 | 粒子状製剤用の凍結保護剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20210137840A1 (https=) |
| EP (3) | EP3784285B1 (https=) |
| JP (2) | JP7256824B2 (https=) |
| KR (2) | KR20210021943A (https=) |
| CN (2) | CN112153986B (https=) |
| AU (2) | AU2019258678B2 (https=) |
| BR (2) | BR112020021037A2 (https=) |
| CA (1) | CA3098259C (https=) |
| ES (2) | ES2960939T3 (https=) |
| MX (2) | MX2020011166A (https=) |
| PL (1) | PL3784285T3 (https=) |
| WO (2) | WO2019207061A1 (https=) |
| ZA (2) | ZA202006026B (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3586861T3 (pl) | 2011-06-08 | 2022-05-23 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna |
| EP3354644A1 (en) | 2011-06-08 | 2018-08-01 | Translate Bio, Inc. | Cleavable lipids |
| ES2762873T3 (es) | 2012-03-29 | 2020-05-26 | Translate Bio Inc | Lípidos catiónicos ionizables |
| SG11201507474QA (en) | 2013-03-14 | 2015-10-29 | Shire Human Genetic Therapies | RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS |
| DK2971098T3 (en) | 2013-03-14 | 2019-02-18 | Translate Bio Inc | QUANTITATIVE ASSESSMENT FOR CAPE EFFECTIVENESS OF MESSENGER RNA |
| CN105051213A (zh) | 2013-03-14 | 2015-11-11 | 夏尔人类遗传性治疗公司 | 信使rna加帽效率的定量评估 |
| KR20210122917A (ko) | 2013-03-14 | 2021-10-12 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna 조성물 및 관련 방법 및 사용 |
| US10130649B2 (en) | 2013-03-15 | 2018-11-20 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| AU2014340149B2 (en) | 2013-10-22 | 2020-12-24 | Shire Human Genetic Therapies, Inc. | CNS delivery of mRNA and uses thereof |
| ES2707966T3 (es) | 2013-10-22 | 2019-04-08 | Translate Bio Inc | Terapia de ARNm para la deficiencia en síntesis de argininosuccinato |
| MX2016005238A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Formulaciones de lipidos para la administracion de acido ribonucleico mensajero. |
| EA034103B1 (ru) | 2013-10-22 | 2019-12-27 | Транслейт Био, Инк. | СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК |
| JP6557722B2 (ja) | 2014-05-30 | 2019-08-07 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 核酸の送達のための生分解性脂質 |
| WO2016090262A1 (en) | 2014-12-05 | 2016-06-09 | Shire Human Genetic Therapies, Inc. | Messenger rna therapy for treatment of articular disease |
| CA3027312A1 (en) | 2016-06-13 | 2017-12-21 | Translate Bio, Inc. | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency |
| MX2019005470A (es) | 2016-11-10 | 2019-11-21 | Translate Bio Inc | Formulación de nanopartículas lipídicas basadas en ice mejorada para el suministro de arnm. |
| WO2018157133A1 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Methods for purification of messenger rna |
| EP4047039A1 (en) | 2017-06-12 | 2022-08-24 | Translate Bio, Inc. | Poly(phosphoesters) for delivery of nucleic acids |
| EP3641834B1 (en) | 2017-06-19 | 2023-10-04 | Translate Bio, Inc. | Messenger rna therapy for the treatment of friedreich's ataxia |
| EP3727428A1 (en) | 2017-12-20 | 2020-10-28 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
| MX2020011166A (es) | 2018-04-25 | 2022-10-19 | Ethris Gmbh | Agentes crioprotectores para formulaciones en forma de particulas. |
| JP7384832B2 (ja) | 2018-05-16 | 2023-11-21 | トランスレイト バイオ， インコーポレイテッド | リボースカチオン性脂質 |
| CN112437767B (zh) | 2018-05-24 | 2023-10-27 | 川斯勒佰尔公司 | 硫酯阳离子脂质 |
| JP7463006B2 (ja) | 2018-05-30 | 2024-04-08 | トランスレイト バイオ， インコーポレイテッド | ステロイド性部分を含むカチオン性脂質 |
| WO2019232095A1 (en) | 2018-05-30 | 2019-12-05 | Translate Bio, Inc. | Vitamin cationic lipids |
| CA3101454A1 (en) | 2018-05-30 | 2019-12-05 | Translate Bio, Inc. | Messenger rna vaccines and uses thereof |
| KR20210056331A (ko) | 2018-07-23 | 2021-05-18 | 트랜슬레이트 바이오 인코포레이티드 | 전령 rna의 건조 분말 제형 |
| EP3836903B1 (en) * | 2018-08-14 | 2024-05-01 | Ethris GmbH | Lipid-based formulations containing salts for the delivery of rna |
| CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| EP3849617A1 (en) | 2018-09-14 | 2021-07-21 | Translate Bio, Inc. | Composition and methods for treatment of methylmalonic acidemia |
| KR20210089648A (ko) | 2018-11-08 | 2021-07-16 | 트랜슬레이트 바이오 인코포레이티드 | 메신저 rna 정제를 위한 방법 및 조성물 |
| MX2021005969A (es) | 2018-11-21 | 2021-09-14 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. |
| WO2020106903A1 (en) | 2018-11-21 | 2020-05-28 | Translate Bio, Inc. | Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna |
| JP2022516356A (ja) | 2019-01-07 | 2022-02-25 | トランスレイト バイオ， インコーポレイテッド | 原発性線毛機能不全症の治療のための組成物および方法 |
| AU2020275885B2 (en) | 2019-05-15 | 2026-02-05 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| EP4003311A1 (en) | 2019-07-23 | 2022-06-01 | Translate Bio, Inc. | Stable compositions of mrna-loaded lipid nanoparticles and processes of making |
| WO2021072172A1 (en) | 2019-10-09 | 2021-04-15 | Translate Bio, Inc. | Compositions, methods and uses of messenger rna |
| WO2021079002A2 (en) | 2019-10-24 | 2021-04-29 | Novago Therapeutics Ag | Novel anti-nogo-a antibodies |
| US12053551B2 (en) | 2019-12-20 | 2024-08-06 | Translate Bio, Inc. | Process of preparing mRNA-loaded lipid nanoparticles |
| JP7744354B2 (ja) | 2020-02-25 | 2025-09-25 | トランスレイト バイオ， インコーポレイテッド | Ｍｒｎａ担持脂質ナノ粒子を調製する改善された方法 |
| US12605399B2 (en) | 2020-05-07 | 2026-04-21 | Translate Bio, Inc. | Compositions for CFTR MRNA therapy |
| WO2021231697A1 (en) | 2020-05-14 | 2021-11-18 | Translate Bio, Inc. | Peg lipidoid compounds |
| US20230242624A1 (en) | 2020-06-02 | 2023-08-03 | Neurimmune Ag | HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) |
| WO2025056938A1 (en) * | 2023-09-11 | 2025-03-20 | BioNTech SE | Rna compositions for delivery of incretin agents |
| EP4229191A1 (en) | 2020-10-15 | 2023-08-23 | Translate Bio, Inc. | Large scale synthesis of messenger rna |
| JP2023548587A (ja) | 2020-11-09 | 2023-11-17 | トランスレイト バイオ， インコーポレイテッド | コドン最適化したｍＲＮＡの送達のための改善された組成物 |
| JP2024527940A (ja) * | 2021-07-26 | 2024-07-26 | モデルナティエックス インコーポレイテッド | ペイロード分子を気道上皮に送達するための脂質ナノ粒子組成物を調製するプロセス |
| CN121844046A (zh) * | 2023-09-11 | 2026-04-10 | C·米库尔卡 | 用于递送肠促胰岛素剂的rna组合物 |
| WO2026006617A1 (en) * | 2024-06-27 | 2026-01-02 | Genentech, Inc. | Lyophilized and frozen mrna-lnp formulations |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| JPS607932A (ja) * | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソーム懸濁液およびその製法 |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| CA2214029A1 (en) * | 1995-04-25 | 1996-10-31 | Magda Marquet | Single-vial formulations of dna/lipid complexes |
| US6017700A (en) | 1995-08-04 | 2000-01-25 | Bayer Corporation | Cationic oligonucleotides, and related methods of synthesis and use |
| BRPI9810945B8 (pt) * | 1997-06-27 | 2021-05-25 | Abraxis Bioscience Inc | formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas |
| TW520294B (en) * | 1998-01-08 | 2003-02-11 | Res Dev Foundation | Stabilization of lipid: DNA formulations during nebulization |
| WO2005121369A2 (en) * | 2004-06-02 | 2005-12-22 | Sourcepharm, Inc. | Rna-containing microvesicles and methods therefor |
| CN1981044B (zh) * | 2004-06-07 | 2010-05-05 | 普洛体维生物治疗公司 | 包封干扰rna的脂质 |
| EP3611266B1 (en) | 2005-08-23 | 2022-11-09 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| WO2008051245A2 (en) * | 2005-12-02 | 2008-05-02 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| RU2451022C2 (ru) | 2005-12-15 | 2012-05-20 | Сантр Насьональ Де Ля Решерш Сьентифик (Снрс) | Катионные олигонуклеотиды, автоматизированные способы их получения и их применение |
| CN101686939B (zh) | 2007-04-17 | 2013-03-27 | 巴克斯特国际公司 | 用于肺部投送的核酸微粒 |
| GB0801876D0 (en) * | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| CN102231979B (zh) * | 2008-10-16 | 2014-10-29 | 玛瑞纳生物技术有限公司 | 基因沉默治疗剂的脂质体有效递送方法和组合物 |
| ES2646630T3 (es) | 2008-11-07 | 2017-12-14 | Massachusetts Institute Of Technology | Lipidoides aminoalcohólicos y usos de los mismos |
| BR112012002291A2 (pt) | 2009-07-31 | 2016-11-29 | Ethris Gmbh | "polirribonucleotídeo com uma sequência que codifica uma proteína ou fragmento de proteína, implante, e, processo para a seleção de sequências de nucleotídeos" |
| WO2011071860A2 (en) | 2009-12-07 | 2011-06-16 | Alnylam Pharmaceuticals, Inc. | Compositions for nucleic acid delivery |
| EP2338520A1 (de) | 2009-12-21 | 2011-06-29 | Ludwig Maximilians Universität | Konjugat mit Zielfindungsligand und dessen Verwendung |
| CN103687588B (zh) * | 2011-05-16 | 2017-04-12 | 丹麦科技大学 | 电荷触发的自组织纳米颗粒 |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| GB201118704D0 (en) * | 2011-10-28 | 2011-12-14 | Univ Oxford | Cystic fibrosis treatment |
| CN104114572A (zh) * | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| EA037448B1 (ru) | 2012-06-08 | 2021-03-30 | Этрис Гмбх | Способ доставки в легкие терапевтической мрнк с pei и фармацевтическая композиция |
| US10130649B2 (en) * | 2013-03-15 | 2018-11-20 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| EP3013964B1 (en) | 2013-06-28 | 2020-05-06 | ethris GmbH | Compositions for introducing rna into cells |
| US9593077B2 (en) | 2013-11-18 | 2017-03-14 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| WO2015128030A1 (en) * | 2014-02-26 | 2015-09-03 | Ethris Gmbh | Compositions for gastrointestinal administration of rna |
| KR102380363B1 (ko) | 2014-11-18 | 2022-03-29 | 아크투루스 쎄라퓨틱스, 인크. | Rna 전달을 위한 이온성 양이온 지질 |
| EP3034539A1 (en) | 2014-12-19 | 2016-06-22 | Ethris GmbH | Compositions for introducing nucleic acid into cells |
| US11219634B2 (en) | 2015-01-21 | 2022-01-11 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| US20180000953A1 (en) * | 2015-01-21 | 2018-01-04 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| WO2018010815A1 (en) * | 2016-07-15 | 2018-01-18 | Biontech Rna Pharmaceuticals Gmbh | Formulation for administration of rna |
| US11583504B2 (en) * | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2018089801A1 (en) | 2016-11-10 | 2018-05-17 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
| MX2020011166A (es) | 2018-04-25 | 2022-10-19 | Ethris Gmbh | Agentes crioprotectores para formulaciones en forma de particulas. |
| EP3836903B1 (en) | 2018-08-14 | 2024-05-01 | Ethris GmbH | Lipid-based formulations containing salts for the delivery of rna |
-
2019
- 2019-04-25 MX MX2020011166A patent/MX2020011166A/es unknown
- 2019-04-25 US US17/050,441 patent/US20210137840A1/en not_active Abandoned
- 2019-04-25 ES ES19718760T patent/ES2960939T3/es active Active
- 2019-04-25 PL PL19718760.2T patent/PL3784285T3/pl unknown
- 2019-04-25 EP EP19718760.2A patent/EP3784285B1/en active Active
- 2019-04-25 BR BR112020021037-4A patent/BR112020021037A2/pt unknown
- 2019-04-25 KR KR1020207030471A patent/KR20210021943A/ko active Pending
- 2019-04-25 US US17/050,440 patent/US12465568B2/en active Active
- 2019-04-25 AU AU2019258678A patent/AU2019258678B2/en not_active Ceased
- 2019-04-25 EP EP23187109.6A patent/EP4311541A3/en not_active Withdrawn
- 2019-04-25 CN CN201980034487.6A patent/CN112153986B/zh not_active Expired - Fee Related
- 2019-04-25 KR KR1020207030470A patent/KR20210022535A/ko not_active Ceased
- 2019-04-25 AU AU2019258679A patent/AU2019258679B2/en active Active
- 2019-04-25 ES ES19718759T patent/ES2960936T3/es active Active
- 2019-04-25 JP JP2020559465A patent/JP7256824B2/ja active Active
- 2019-04-25 MX MX2020011167A patent/MX2020011167A/es unknown
- 2019-04-25 WO PCT/EP2019/060646 patent/WO2019207061A1/en not_active Ceased
- 2019-04-25 JP JP2020558887A patent/JP2021522228A/ja active Pending
- 2019-04-25 BR BR112020021054-4A patent/BR112020021054A2/pt unknown
- 2019-04-25 EP EP19718759.4A patent/EP3784284B1/en active Active
- 2019-04-25 WO PCT/EP2019/060644 patent/WO2019207060A1/en not_active Ceased
- 2019-04-25 CN CN201980034447.1A patent/CN112153985B/zh active Active
- 2019-04-25 CA CA3098259A patent/CA3098259C/en active Active
-
2020
- 2020-09-29 ZA ZA2020/06026A patent/ZA202006026B/en unknown
- 2020-09-29 ZA ZA2020/06025A patent/ZA202006025B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522228A5 (https=) | ||
| JPWO2019207060A5 (https=) | ||
| JP2021522248A5 (https=) | ||
| JPWO2019207061A5 (https=) | ||
| JP2020510015A5 (https=) | ||
| Rubin et al. | Emerging aerosol drug delivery strategies: from bench to clinic | |
| JP2011051993A5 (https=) | ||
| JP2016506916A5 (https=) | ||
| JP2017528498A5 (https=) | ||
| JP2016516066A5 (https=) | ||
| JP2012530703A5 (https=) | ||
| JP2020537501A5 (https=) | ||
| JP2003503420A5 (https=) | ||
| JP2014521688A5 (https=) | ||
| JP2014077003A5 (https=) | ||
| JP2007500229A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| CN114409554A (zh) | 一种新型阳离子脂质化合物及其组合物和用途 | |
| JP2016535094A5 (https=) | ||
| JP2001520656A (ja) | 抗腫瘍剤としてのホルボールエステル類 | |
| JP5873656B2 (ja) | 金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤 | |
| BR102012026195A2 (pt) | Método de produção de um medicamento de nicotina e um medicamento feito pelo método | |
| CN109152763A (zh) | 含有青蒿琥酯的组合物 | |
| RU2010137337A (ru) | Способы и композиции для лечения респираторных заболеваний | |
| TW200401653A (en) | Aerosol formulation for inhalation containing a tiotropium salt |